Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BI10773 Clear all
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Early Phase 1 Interventional

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

NCT05057806
View directory record Official record
Conditions
Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
Interventions
Empagliflozin 25 MG, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Not listed Early Phase 1 Interventional

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

NCT04203927
View directory record Official record
Conditions
Type2 Diabetes, Insulin Sensitivity
Interventions
Empagliflozin 25 MG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Phase 3 Interventional

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions
Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
11,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
208
States / cities
Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

NCT07175051
View directory record Official record
Conditions
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Interventions
Empagliflozin (oral)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

NCT06745063
View directory record Official record
Conditions
Obesity, Vascular Health
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

NCT04509674
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
85
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

NCT03448406
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

NCT01867307
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Healthy
Interventions
Empagliflozin, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

NCT03594110
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Empagliflozin, Matching placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Huntsville, Alabama • Mesa, Arizona • San Diego, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288
View directory record Official record
Conditions
Heart Failure
Interventions
vicadrostat, empagliflozin, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
94
States / cities
Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Phase 1 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT02106923
View directory record Official record
Conditions
Healthy
Interventions
1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 26, 2026, 9:32 AM EDT
Not listed No phase listed Observational

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

NCT03627039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SGLT2, Metformin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

NCT03448419
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Results available

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

NCT03852901
View directory record Official record
Conditions
Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
Interventions
empagliflozin (Jardiance) 25 mg
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 26, 2026, 9:32 AM EDT
Recruiting Phase 4 Interventional

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892
View directory record Official record
Conditions
Type2Diabetes, ASCVD
Interventions
SGLT2 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
36
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 26, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

NCT03351478
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Empagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 26, 2026, 9:32 AM EDT